The typical metabolic modifiers conferring improvement in cancer resistance

Wen Tan, Zhangfeng Zhong, Shengpeng Wang, Hui Liu, Hua Yu, Rui Tan, Xiaodong Hu, Tingrui Pan, Yitao Wang

Research output: Contribution to journalReview article

5 Citations (Scopus)

Abstract

Background: Cancer metabolic reprogramming rekindles enthusiasm for the research of metabolic regulation in cancer drug resistance. A growing number of metabolic modifiers combined with cancer drugs obtain the expected efficacy in in vitro or in vivo studies, also in clinical trial studies, indicating a good potential of enhancing efficacy and reducing resistance. Hence, a comprehensive review on the attenuations of metabolic modifiers in cancer drug resistance is necessary for rational drug design and clinical cancer drug research. Methods: Cancer drug resistance and cancer metabolic reprogramming were used as the key words to collect publications with reference value in bibliographic databases. Specifically, the focused question is the advances of metabolic modifiers on cancer resistance improvement. Figures and tables were applied to analyze the interventions in accordance with the inclusion criteria. Results: This review summarized the advances of metabolic modifiers combined with cancer drugs in in vitro, in vivo and clinical trial studies, especially for cancer resistance improvement. The relationship between metabolic regulation and cancer resistance was elaborated, and the potential metabolic modifiers were embraced. Metabolic targets were also visualized in categorization in 4 figures and expatiated in 4 tables. Three typical metabolic modifiers, namely lonidamine, 2-DG and 3-BrPA, conferring attenuation to cancer resistance were elucidated systematically. Conclusion: Metabolic regulation is an intervention with targeted perturbation in a modest manner and reflects homeostasis balance. When combined with cancer drugs, the metabolic modifiers always show exciting potential with practical significance, enhancing activity or exerting synergism.

Original languageEnglish (US)
Pages (from-to)3698-3710
Number of pages13
JournalCurrent Medicinal Chemistry
Volume24
Issue number34
DOIs
StatePublished - Oct 1 2017

Fingerprint

Pharmaceutical Preparations
Neoplasms
Drug Resistance
Clinical Trials
Bibliographic Databases
Drug Design
Research
Publications
Reference Values
Homeostasis

Keywords

  • 2-deoxy-Dglucose
  • 3-bromopyruvate
  • Cancer metabolic reprogramming
  • Cancer resistance
  • Lonidamine
  • Metabolic modifiers

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology

Cite this

The typical metabolic modifiers conferring improvement in cancer resistance. / Tan, Wen; Zhong, Zhangfeng; Wang, Shengpeng; Liu, Hui; Yu, Hua; Tan, Rui; Hu, Xiaodong; Pan, Tingrui; Wang, Yitao.

In: Current Medicinal Chemistry, Vol. 24, No. 34, 01.10.2017, p. 3698-3710.

Research output: Contribution to journalReview article

Tan, W, Zhong, Z, Wang, S, Liu, H, Yu, H, Tan, R, Hu, X, Pan, T & Wang, Y 2017, 'The typical metabolic modifiers conferring improvement in cancer resistance', Current Medicinal Chemistry, vol. 24, no. 34, pp. 3698-3710. https://doi.org/10.2174/0929867324666170203121449
Tan, Wen ; Zhong, Zhangfeng ; Wang, Shengpeng ; Liu, Hui ; Yu, Hua ; Tan, Rui ; Hu, Xiaodong ; Pan, Tingrui ; Wang, Yitao. / The typical metabolic modifiers conferring improvement in cancer resistance. In: Current Medicinal Chemistry. 2017 ; Vol. 24, No. 34. pp. 3698-3710.
@article{2bdc3c2eaf014bfeaf9ac0b8bc8a9b91,
title = "The typical metabolic modifiers conferring improvement in cancer resistance",
abstract = "Background: Cancer metabolic reprogramming rekindles enthusiasm for the research of metabolic regulation in cancer drug resistance. A growing number of metabolic modifiers combined with cancer drugs obtain the expected efficacy in in vitro or in vivo studies, also in clinical trial studies, indicating a good potential of enhancing efficacy and reducing resistance. Hence, a comprehensive review on the attenuations of metabolic modifiers in cancer drug resistance is necessary for rational drug design and clinical cancer drug research. Methods: Cancer drug resistance and cancer metabolic reprogramming were used as the key words to collect publications with reference value in bibliographic databases. Specifically, the focused question is the advances of metabolic modifiers on cancer resistance improvement. Figures and tables were applied to analyze the interventions in accordance with the inclusion criteria. Results: This review summarized the advances of metabolic modifiers combined with cancer drugs in in vitro, in vivo and clinical trial studies, especially for cancer resistance improvement. The relationship between metabolic regulation and cancer resistance was elaborated, and the potential metabolic modifiers were embraced. Metabolic targets were also visualized in categorization in 4 figures and expatiated in 4 tables. Three typical metabolic modifiers, namely lonidamine, 2-DG and 3-BrPA, conferring attenuation to cancer resistance were elucidated systematically. Conclusion: Metabolic regulation is an intervention with targeted perturbation in a modest manner and reflects homeostasis balance. When combined with cancer drugs, the metabolic modifiers always show exciting potential with practical significance, enhancing activity or exerting synergism.",
keywords = "2-deoxy-Dglucose, 3-bromopyruvate, Cancer metabolic reprogramming, Cancer resistance, Lonidamine, Metabolic modifiers",
author = "Wen Tan and Zhangfeng Zhong and Shengpeng Wang and Hui Liu and Hua Yu and Rui Tan and Xiaodong Hu and Tingrui Pan and Yitao Wang",
year = "2017",
month = "10",
day = "1",
doi = "10.2174/0929867324666170203121449",
language = "English (US)",
volume = "24",
pages = "3698--3710",
journal = "Current Medicinal Chemistry",
issn = "0929-8673",
publisher = "Bentham Science Publishers B.V.",
number = "34",

}

TY - JOUR

T1 - The typical metabolic modifiers conferring improvement in cancer resistance

AU - Tan, Wen

AU - Zhong, Zhangfeng

AU - Wang, Shengpeng

AU - Liu, Hui

AU - Yu, Hua

AU - Tan, Rui

AU - Hu, Xiaodong

AU - Pan, Tingrui

AU - Wang, Yitao

PY - 2017/10/1

Y1 - 2017/10/1

N2 - Background: Cancer metabolic reprogramming rekindles enthusiasm for the research of metabolic regulation in cancer drug resistance. A growing number of metabolic modifiers combined with cancer drugs obtain the expected efficacy in in vitro or in vivo studies, also in clinical trial studies, indicating a good potential of enhancing efficacy and reducing resistance. Hence, a comprehensive review on the attenuations of metabolic modifiers in cancer drug resistance is necessary for rational drug design and clinical cancer drug research. Methods: Cancer drug resistance and cancer metabolic reprogramming were used as the key words to collect publications with reference value in bibliographic databases. Specifically, the focused question is the advances of metabolic modifiers on cancer resistance improvement. Figures and tables were applied to analyze the interventions in accordance with the inclusion criteria. Results: This review summarized the advances of metabolic modifiers combined with cancer drugs in in vitro, in vivo and clinical trial studies, especially for cancer resistance improvement. The relationship between metabolic regulation and cancer resistance was elaborated, and the potential metabolic modifiers were embraced. Metabolic targets were also visualized in categorization in 4 figures and expatiated in 4 tables. Three typical metabolic modifiers, namely lonidamine, 2-DG and 3-BrPA, conferring attenuation to cancer resistance were elucidated systematically. Conclusion: Metabolic regulation is an intervention with targeted perturbation in a modest manner and reflects homeostasis balance. When combined with cancer drugs, the metabolic modifiers always show exciting potential with practical significance, enhancing activity or exerting synergism.

AB - Background: Cancer metabolic reprogramming rekindles enthusiasm for the research of metabolic regulation in cancer drug resistance. A growing number of metabolic modifiers combined with cancer drugs obtain the expected efficacy in in vitro or in vivo studies, also in clinical trial studies, indicating a good potential of enhancing efficacy and reducing resistance. Hence, a comprehensive review on the attenuations of metabolic modifiers in cancer drug resistance is necessary for rational drug design and clinical cancer drug research. Methods: Cancer drug resistance and cancer metabolic reprogramming were used as the key words to collect publications with reference value in bibliographic databases. Specifically, the focused question is the advances of metabolic modifiers on cancer resistance improvement. Figures and tables were applied to analyze the interventions in accordance with the inclusion criteria. Results: This review summarized the advances of metabolic modifiers combined with cancer drugs in in vitro, in vivo and clinical trial studies, especially for cancer resistance improvement. The relationship between metabolic regulation and cancer resistance was elaborated, and the potential metabolic modifiers were embraced. Metabolic targets were also visualized in categorization in 4 figures and expatiated in 4 tables. Three typical metabolic modifiers, namely lonidamine, 2-DG and 3-BrPA, conferring attenuation to cancer resistance were elucidated systematically. Conclusion: Metabolic regulation is an intervention with targeted perturbation in a modest manner and reflects homeostasis balance. When combined with cancer drugs, the metabolic modifiers always show exciting potential with practical significance, enhancing activity or exerting synergism.

KW - 2-deoxy-Dglucose

KW - 3-bromopyruvate

KW - Cancer metabolic reprogramming

KW - Cancer resistance

KW - Lonidamine

KW - Metabolic modifiers

UR - http://www.scopus.com/inward/record.url?scp=85038222811&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85038222811&partnerID=8YFLogxK

U2 - 10.2174/0929867324666170203121449

DO - 10.2174/0929867324666170203121449

M3 - Review article

C2 - 28164760

AN - SCOPUS:85038222811

VL - 24

SP - 3698

EP - 3710

JO - Current Medicinal Chemistry

JF - Current Medicinal Chemistry

SN - 0929-8673

IS - 34

ER -